Vision 2020 has been instrumental in advocacy efforts by securing sufficient resources and the commitment to achieve its objectives.29, 30 Additionally, the emergence of novel medical resources such as anti-vascular endothelial growth factor (anti-VEGF) agents (eg, ranibizumab, aflibercept, faricimab, brolucizumab, and bevacizumab)9, 17 and ongoing research on treatments for non-exudative AMD, particularly geographic atrophy (eg, pegcetacoplan and avacincaptad pegol),31 might have contributed to the decline in DALY rates. This evidence concerns the gene VEGFA and age-related macular degeneration.